JAVMA study links renal diets to longer survival in CKD cats: full analysis

A newly published JAVMA study is giving veterinary teams stronger evidence for something long debated in feline medicine: whether a veterinary therapeutic renal diet is worth starting in cats before CKD becomes advanced. According to the retrospective analysis, cats with early-stage CKD that were continuously fed a renal diet had slower progression and longer survival than cats that were not treated with one. In practical terms, survival over three years was 31 months versus 26 months, a five-month difference, and Stage 1 cats had a 45% lower hazard of progression. (pubmed.ncbi.nlm.nih.gov)

The study, published online January 14, 2026, analyzed medical records from veterinary practices in the US and Canada. Investigators reviewed 1,430 cats born between January 1, 2010, and December 31, 2014, that were diagnosed with early-stage CKD. Of those, 839 received a veterinary therapeutic renal diet and 591 did not. The authors, led by Michael Coyne, included researchers from IDEXX Laboratories as well as independent contributors and a private practice veterinarian. (pubmed.ncbi.nlm.nih.gov)

The progression data are likely to get the most attention in practice. In the PubMed abstract, treated Stage 1 cats had a hazard ratio of 0.55 for progression, while treated Stage 2 cats had hazard ratios of 0.54 or 0.59 depending on creatinine grouping. IDEXX’s renal care summary adds more operational detail, reporting approximate times to progression of 20 months versus 9 months in Stage 1 cats, 28 months versus 9 months in early Stage 2 cats, and 21 months versus 12 months in later Stage 2 cats. The same summary reports an overall mortality hazard ratio of 0.70, with all-cause mortality measured across the three-year analysis window. (pubmed.ncbi.nlm.nih.gov)

The bigger context is that this study lands in a field already oriented toward earlier detection and earlier intervention. IDEXX has spent years building its kidney-health portfolio around earlier CKD identification, including SDMA testing and, more recently, FGF-23 testing for cats with CKD. On its kidney health page, the company says the FGF-23 test is now included in the 2023 IRIS treatment recommendations for cats and can help inform diet changes in Stage 1 and 2 disease. Independent guideline literature has also pushed clinicians to introduce renal diets early, with ISFM guidance recommending renal diet use as early as possible in Stage 2 CKD. (idexx.com)

Direct outside commentary on this specific 2026 JAVMA paper appears limited so far, but the broader expert view is consistent: nutritional management is a central part of CKD care, and the challenge is often not whether renal diets work, but whether cats will accept them and whether pet parents will commit early enough. Royal Canin Academy notes that therapeutic renal diets are part of early CKD management, while Vet Times and other clinical education sources emphasize gradual transition, monitoring tolerance, and considering alternatives when acceptance is poor. That makes this study less of a conceptual surprise than a useful piece of real-world evidence with a large sample size. (academy.royalcanin.com)

Why it matters: For veterinary professionals, the study strengthens the case for making the renal-diet conversation a first-line recommendation, not a late-stage add-on. In early CKD, many cats are asymptomatic, and pet parents may hesitate to switch food when the cat still seems well. This dataset gives clinicians a more concrete way to frame the benefit: earlier diet intervention was associated with about one extra year before progression in Stage 1 cats, and about five additional months of survival overall. It also supports the business and workflow case for routine screening, because the value of identifying early CKD is much higher if practices can pair diagnosis with a change that improves outcomes. (pubmed.ncbi.nlm.nih.gov)

There are still important caveats. This was a retrospective observational study, not a randomized clinical trial, so it shows association rather than proving causation. The paper also evaluated cats that were continuously treated with a renal diet, which may select for pet parents who were better able to follow through with recommendations and rechecks. Even so, the size of the dataset and the consistency of the signal across early stages make the findings hard to ignore. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next question is whether these findings shift everyday practice, especially for IRIS Stage 1 cats and cats with early biomarker changes but few outward signs. Watch for more discussion in CE, nutrition guidance, and clinical protocols around earlier renal diet initiation, plus more attention to transition strategies that improve acceptance and adherence at home. (ca.idexx.com)